{"id":3367,"date":"2026-09-01T21:53:03","date_gmt":"2026-09-01T20:53:03","guid":{"rendered":"https:\/\/wheat-quail-856400.hostingersite.com\/?p=3367"},"modified":"2026-11-12T18:50:56","modified_gmt":"2026-11-12T17:50:56","slug":"car-t-cell-expansion-hpl-vs-fbs","status":"publish","type":"post","link":"https:\/\/seamlessbio.de\/de\/car-t-cell-expansion-hpl-vs-fbs\/","title":{"rendered":"CAR-T-Zell-Expansion \u2013 hPL vs. FKS"},"content":{"rendered":"<p><!--\nWORDPRESS BLOG POST\nSlug: car-t-cell-expansion-hpl-vs-fbs\nSEO Title: CAR-T Cell Expansion \u2014 hPL vs FBS \u2014 What the Data Shows | SeamlessBio\nMeta Description: A data-driven comparison of human platelet lysate (hPL) and FBS for CAR-T cell manufacturing \u2014 expansion rate, phenotype, exhaustion markers, and regulatory considerations.\nFocus Keyword: CAR-T cell expansion hPL vs FBS\nAdditional Keywords: human platelet lysate CAR-T manufacturing, FBS vs hPL T cell expansion, xeno-free CAR-T medium, CAR-T ATMP manufacturing serum\nCategory: Cell Therapy \u00b7 ATMP \u00b7 CAR-T\n--><\/p>\n<style>\n.sb-bp{font-family:-apple-system,BlinkMacSystemFont,\"Segoe UI\",Roboto,sans-serif;max-width:780px;margin:0 auto;padding:0 0 60px;color:#202020;line-height:1.75}\n.sb-bp .lede{font-size:18px;font-weight:500;color:#3a4a50;border-left:4px solid #18b7b2;padding-left:20px;margin:0 0 32px;line-height:1.65}\n.sb-bp h2{font-size:24px;font-weight:800;margin:44px 0 14px;color:#111;padding-bottom:10px;border-bottom:2px solid #e2eceb}\n.sb-bp h3{font-size:18px;font-weight:700;margin:32px 0 10px;color:#18b7b2}\n.sb-bp p{margin:0 0 18px}\n.sb-bp ul,.sb-bp ol{margin:0 0 18px;padding-left:24px}\n.sb-bp li{margin-bottom:8px}\n.sb-bp table{width:100%;border-collapse:collapse;font-size:14px;margin:20px 0 28px;display:block;overflow-x:auto}\n.sb-bp th{background:#18b7b2;color:#fff;text-align:left;padding:10px 14px;font-weight:700;white-space:nowrap}\n.sb-bp td{padding:10px 14px;border-bottom:1px solid #e2eceb;vertical-align:top}\n.sb-bp tr:last-child td{border-bottom:none}\n.sb-bp td:first-child{font-weight:600;color:#111}\n.sb-bp a{color:#18b7b2;text-decoration:none;font-weight:600}\n.sb-bp strong{color:#111}\n.sb-bp .box{background:#f1faf9;border-left:4px solid #18b7b2;border-radius:0 12px 12px 0;padding:20px 24px;margin:28px 0}\n.sb-bp .warn{background:#fff8e1;border-left:4px solid #f59e0b;border-radius:0 12px 12px 0;padding:20px 24px;margin:28px 0}\n.sb-bp .cta-box{background:linear-gradient(135deg,#e4f6f5,#f4fbfb);border:1px solid rgba(24,183,178,.2);border-radius:16px;padding:28px;margin-top:44px;text-align:center}\n.sb-bp .cta-box h3{color:#111;margin:0 0 10px;font-size:20px}\n.sb-bp .cta-box p{color:#5b6b71;margin:0 0 18px}\n.sb-bp .cta-btns{display:flex;justify-content:center;gap:12px;flex-wrap:wrap}\n.sb-bp .btn{display:inline-block;background:#18b7b2;color:#fff!important;padding:10px 22px;border-radius:8px;font-weight:700;font-size:14px;text-decoration:none!important}\n.sb-bp .btn-o{display:inline-block;border:2px solid #18b7b2;color:#18b7b2!important;padding:8px 22px;border-radius:8px;font-weight:700;font-size:14px;text-decoration:none!important}\n<\/style>\n<div class=\"sb-bp\">\n<p class=\"lede\">Der Wechsel von FKS zu humanem Thrombozytenlysat (hPL) in der CAR-T-Zell-Herstellung ist keine blo\u00dfe regulatorische Vorliebe mehr \u2013 er wird zum De-facto-Standard f\u00fcr die Produktion in klinischer Qualit\u00e4t. Doch die Entscheidung ist nicht nur regulatorisch. Immer mehr ver\u00f6ffentlichte Daten zeigen, dass in hPL expandierte T-Zellen sich funktionell auf therapeutisch relevante Weise von in FKS expandierten unterscheiden. Dieser Beitrag fasst zusammen, was die Daten zeigen.<\/p>\n<p><!-- BUY BOX (SEO: links to buy pages) --><\/p>\n<div class=\"sb-buy-box\" style=\"border:1px solid #cfe9e6;background:#f4fbfa;border-radius:12px;padding:22px 26px;margin:28px auto;max-width:1200px;box-sizing:border-box\">\n<h2 style=\"font-size:22px;line-height:1.3;margin:0 0 6px\">hPL und humanes AB-Serum bestellen<\/h2>\n<p style=\"margin:0 0 14px\">Angebot oder Testmuster anfordern \u2013 Lager in der EU, ohne Mindestmenge, Chargenreservierung bis zu 36 Monate.<\/p>\n<ul style=\"margin:0;padding-left:20px;columns:2 300px;column-gap:32px\">\n<li style=\"margin:0 0 6px\"><a href=\"https:\/\/seamlessbio.de\/de\/produkt\/humanes-thrombozytenlysat-hpl-gmp-eu\/\">Humanes Thrombozytenlysat (hPL) \u2013 EU-Herkunft<\/a><\/li>\n<li style=\"margin:0 0 6px\"><a href=\"https:\/\/seamlessbio.de\/de\/produkt\/human-serum-type-ab-male-off-the-clot-xeno-free-eu-origin\/\">M\u00e4nnliches AB-Serum Off-the-Clot \u2013 xenofrei, EU-Herkunft<\/a><\/li>\n<li style=\"margin:0 0 6px\"><a href=\"https:\/\/seamlessbio.de\/de\/produkt\/human-serum-type-ab-male-eu-us-origin-sterile\/\">Humanserum Typ AB m\u00e4nnlich \u2013 EU\/US-Herkunft<\/a><\/li>\n<li style=\"margin:0 0 6px\"><a href=\"https:\/\/seamlessbio.de\/de\/request-quote\/\">Angebot oder Testmuster anfordern<\/a><\/li>\n<\/ul>\n<\/div>\n<h2>Warum die Serumquelle f\u00fcr die T-Zell-Biologie wichtig ist<\/h2>\n<p>T-Zellen reagieren w\u00e4hrend der Ex-vivo-Expansion \u00e4u\u00dferst empfindlich auf ihr Zytokin- und Wachstumsfaktormilieu. Der Serumzusatz ist nicht nur N\u00e4hrstoffquelle, sondern ein komplexes biologisches Signal, das Ph\u00e4notyp, Ersch\u00f6pfungsstatus und Ged\u00e4chtnisdifferenzierung der T-Zellen pr\u00e4gt \u2013 und damit letztlich ihre Persistenz nach der Infusion. Zwei Serumquellen, die auf dem CoA \u00e4hnlich aussehen, k\u00f6nnen T-Zellen mit grundlegend unterschiedlichen funktionellen Profilen hervorbringen.<\/p>\n<p>FKS liefert bovine Wachstumsfaktoren \u2013 IGF-1, TGF-\u03b2, PDGF, EGF \u2013, die nicht artgleich zu den Rezeptoren humaner T-Zellen passen. Humanes Thrombozytenlysat liefert die menschlichen Entsprechungen dieser Faktoren, die bei der Gefrier-Tau-Lyse aus den \u03b1-Granula der Thrombozyten freigesetzt werden. F\u00fcr humane T-Zellen wirken artgleiche Wachstumsfaktoren schon in geringerer Konzentration st\u00e4rker \u2013 deshalb kann hPL mit 5 % eine schnellere Expansion antreiben als FKS mit 10 %.<\/p>\n<h2>Die ver\u00f6ffentlichten Daten \u2013 Expansionsrate<\/h2>\n<p>Mehrere ver\u00f6ffentlichte Studien haben FKS und hPL f\u00fcr die Expansion prim\u00e4rer humaner T-Zellen und CAR-T-Zellen verglichen. Das \u00fcbereinstimmende Ergebnis:<\/p>\n<table>\n<thead>\n<tr>\n<th>Studienparameter<\/th>\n<th>FKS (10 %)<\/th>\n<th>hPL (5 %)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Expansionsfaktor (14 Tage)<\/td>\n<td>100\u2013300\u00d7<\/td>\n<td>300\u20131,000\u00d7<\/td>\n<\/tr>\n<tr>\n<td>Populationsverdopplungszeit<\/td>\n<td>18\u201324h<\/td>\n<td>14\u201320h<\/td>\n<\/tr>\n<tr>\n<td>Zellviabilit\u00e4t<\/td>\n<td>85\u201395%<\/td>\n<td>90\u201397%<\/td>\n<\/tr>\n<tr>\n<td>Erhalt des CD4:CD8-Verh\u00e4ltnisses<\/td>\n<td>Variabel \u2013 chargenabh\u00e4ngig<\/td>\n<td>Stabiler \u00fcber hPL-Chargen hinweg<\/td>\n<\/tr>\n<tr>\n<td>CD3+-Reinheit nach der Expansion<\/td>\n<td>Vergleichbar<\/td>\n<td>Vergleichbar<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Die h\u00f6here Expansionsrate in hPL beruht vor allem auf h\u00f6heren Konzentrationen von humanem PDGF-AB\/BB und EGF aus den \u03b1-Granula der Thrombozyten \u2013 beide signalisieren \u00fcber Rezeptoren auf aktivierten T-Zellen und treiben die Proliferation wirksamer an als ihre bovinen Entsprechungen im FKS.<\/p>\n<h2>Der entscheidende Unterschied \u2013 T-Zell-Ph\u00e4notyp und Ersch\u00f6pfung<\/h2>\n<p>Die Expansionsrate allein ist in der CAR-T-Herstellung nicht die ma\u00dfgebliche Kenngr\u00f6\u00dfe. Entscheidend ist der Ph\u00e4notyp der expandierten Zellen \u2013 vor allem Ged\u00e4chtnisdifferenzierung und Expression von Ersch\u00f6pfungsmarkern, die Persistenz und therapeutische Wirksamkeit nach der Infusion direkt vorhersagen.<\/p>\n<p>Die Ged\u00e4chtnisdifferenzierung von T-Zellen folgt einer Hierarchie: naiv (Tnaive) \u2192 Stammzell-Ged\u00e4chtnis (Tscm) \u2192 zentrales Ged\u00e4chtnis (Tcm) \u2192 Effektor-Ged\u00e4chtnis (Tem) \u2192 terminal differenzierte Effektorzellen (Teff). Weniger differenzierte Zellen (Tscm, Tcm) persistieren in vivo l\u00e4nger und sind mit besseren klinischen Ansprechraten in der CAR-T-Therapie verbunden. St\u00e4rker differenzierte Zellen (Tem, Teff) expandieren in vitro schnell, ersch\u00f6pfen sich aber nach der Infusion rasch.<\/p>\n<table>\n<thead>\n<tr>\n<th>Ph\u00e4notypmarker<\/th>\n<th>In FKS expandierte T-Zellen<\/th>\n<th>In hPL expandierte T-Zellen<\/th>\n<th>Klinische Relevanz<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>CD62L+ (zentrales Ged\u00e4chtnis)<\/td>\n<td>Niedriger \u2013 st\u00e4rker differenziert<\/td>\n<td>H\u00f6her \u2013 weniger differenziert<\/td>\n<td>Mehr CD62L \u2192 bessere Persistenz in vivo<\/td>\n<\/tr>\n<tr>\n<td>CCR7+ (Lymphknoten-Homing)<\/td>\n<td>Nach unten<\/td>\n<td>H\u00f6her<\/td>\n<td>Mehr CCR7 \u2192 bessere Gewebemigration<\/td>\n<\/tr>\n<tr>\n<td>PD-1 (Ersch\u00f6pfungsmarker)<\/td>\n<td>H\u00f6here Expression<\/td>\n<td>Niedrigere Expression<\/td>\n<td>Weniger PD-1 \u2192 weniger Ersch\u00f6pfung, bessere Aktivit\u00e4t<\/td>\n<\/tr>\n<tr>\n<td>TIM-3 (Ersch\u00f6pfungsmarker)<\/td>\n<td>H\u00f6here Expression<\/td>\n<td>Niedrigere Expression<\/td>\n<td>Weniger TIM-3 \u2192 l\u00e4ngere funktionelle Lebensdauer<\/td>\n<\/tr>\n<tr>\n<td>LAG-3 (Ersch\u00f6pfungsmarker)<\/td>\n<td>H\u00f6here Expression<\/td>\n<td>Niedrigere Expression<\/td>\n<td>Weniger LAG-3 \u2192 weniger koinhibitorische Signale<\/td>\n<\/tr>\n<tr>\n<td>Ki-67 (Proliferation)<\/td>\n<td>Niedriger an Tag 14<\/td>\n<td>H\u00f6her an Tag 14<\/td>\n<td>Mehr proliferierende Zellen \u2192 besseres Engraftment<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<div class=\"box\">\n<strong>Das zentrale Ergebnis:<\/strong> In FKS expandierte T-Zellen zeigen im Vergleich zu in hPL expandierten T-Zellen desselben Spenders eine h\u00f6here Expression von Ersch\u00f6pfungsmarkern (PD-1, TIM-3, LAG-3) und einen geringeren Anteil zentraler Ged\u00e4chtniszellen (CD62L+, CCR7+). Das best\u00e4tigen mehrere unabh\u00e4ngige Studien; zur\u00fcckgef\u00fchrt wird es auf die TGF-\u03b2-Signalgebung \u2013 bovines TGF-\u03b2 im FKS treibt die T-Zell-Differenzierung st\u00e4rker in Richtung eines ersch\u00f6pften Ph\u00e4notyps als die humanen Entsprechungen im hPL.\n<\/div>\n<h2>Besonderheiten bei CAR-T<\/h2>\n<p>Speziell bei CAR-T-Zellen (im Unterschied zu polyklonalen T-Zell-Therapien) beeinflusst die Serumquelle nicht nur die Expansion der nicht transduzierten T-Zellen, sondern auch die Transduktionseffizienz des lentiviralen oder retroviralen Vektors, mit dem das CAR-Konstrukt eingebracht wird:<\/p>\n<ul>\n<li><strong>Lentivirale Transduktionseffizienz:<\/strong> In hPL expandierte T-Zellen zeigen eine vergleichbare oder h\u00f6here lentivirale Transduktionseffizienz als in FKS expandierte \u2013 trotz schnellerer Proliferation (die das integrierte Provirus verd\u00fcnnen kann). Die h\u00f6here Viabilit\u00e4t der in hPL expandierten Zellen zum Zeitpunkt der Transduktion k\u00f6nnte das erkl\u00e4ren<\/li>\n<li><strong>Stabilit\u00e4t der CAR-Expression:<\/strong> Die CAR-Expression (gemessen als CAR-Oberfl\u00e4chendichte und MFI) ist nach der Transduktion unter FKS- und hPL-Bedingungen vergleichbar<\/li>\n<li><strong>Zytotoxische Funktion:<\/strong> In hPL expandierte CAR-T-Zellen t\u00f6ten Zielzellen in Co-Kultur-Assays gleich gut oder besser \u2013 passend zur geringeren Expression von Ersch\u00f6pfungsmarkern<\/li>\n<\/ul>\n<h2>Regulatorische Aspekte \u2013 warum hPL zunehmend verpflichtend wird<\/h2>\n<p>Die EMA-Leitlinien zu neuartigen Therapien empfehlen nachdr\u00fccklich, xenogene (tierische) Bestandteile aus der ATMP-Herstellung zu eliminieren. FKS bringt mit sich:<\/p>\n<ul>\n<li>TSE\/BSE-Risiko mit Herkunftszertifizierung und chargenspezifischer Dokumentation<\/li>\n<li>Risiko durch Fremdagenzien (BVDV, andere bovine Viren) mit Pr\u00fcfung je Charge<\/li>\n<li>M\u00f6gliche Immunogenit\u00e4t boviner Proteine im fertigen Zellprodukt (an T-Zell-Oberfl\u00e4chen adsorbierte FKS-Restproteine)<\/li>\n<li>Chargenvariabilit\u00e4t, die den Nachweis der Prozesskonsistenz in IND\/CTA erschwert<\/li>\n<\/ul>\n<p>Humanes Thrombozytenlysat von gescreenten menschlichen Spendern mit Ethikvotum und vollst\u00e4ndiger Dokumentation beseitigt alle bovinspezifischen Risiken und vereinfacht die Risikobewertung der ATMP-Rohstoffe erheblich.<\/p>\n<h2>Praktische Umsetzung \u2013 von FKS auf hPL umsteigen<\/h2>\n<p>Der Umstieg von FKS auf hPL in der T-Zell-Expansion ist unkompliziert, erfordert aber Aufmerksamkeit bei zwei Punkten:<\/p>\n<p><strong>1. Fibrinogen:<\/strong> hPL enth\u00e4lt 2\u20134 mg\/ml Fibrinogen \u2013 bei K\u00f6rpertemperatur kann es im T-Zell-Kulturmedium ein Gel bilden, das die Suspensionskultur st\u00f6rt. Heparin mit 2 IE\/ml verhindert die Fibringelbildung. Alternativ fibrinogen-abgereicherte hPL-Formulierungen verwenden.<\/p>\n<p><strong>2. Konzentration:<\/strong> hPL mit 5 % reicht in der Regel \u2013 h\u00f6here Konzentrationen (7,5\u201310 %) k\u00f6nnen in den ersten 48\u201372 Stunden nach der Aktivierung eingesetzt werden, sind aber \u00fcber die gesamte Expansion meist nicht n\u00f6tig. Durch die h\u00f6here Wachstumsfaktordichte \u00fcbertrifft 5 % hPL meist 10 % FKS \u2013 die Kosten sind daher trotz des h\u00f6heren Literpreises von hPL vergleichbar.<\/p>\n<div class=\"cta-box\">\n<h3>Humanes Thrombozytenlysat f\u00fcr die CAR-T- und T-Zell-Expansion<\/h3>\n<p>SeamlessBio liefert GMP-kompatibles humanes Thrombozytenlysat (hPL) \u2013 xenofrei, mit vollst\u00e4ndiger Spenderdokumentation und Ethikvotum, in Forschungs- und GMP-Qualit\u00e4t. Angebot innerhalb von 48 Stunden.<\/p>\n<div class=\"cta-btns\">\n<a href=\"https:\/\/seamlessbio.de\/de\/humanes-thrombozytenlysat-hpl\/\" class=\"btn-o\">Humanes Thrombozytenlysat (hPL) (hPL) \u2192<\/a><br \/>\n<a href=\"https:\/\/seamlessbio.de\/de\/what-is-human-platelet-lysate-hpl\/\" class=\"btn-o\">Was ist hPL? \u2192<\/a><br \/>\n<a href=\"https:\/\/seamlessbio.de\/de\/ressourcen\/blog\/human-platelet-lysate-hpl-fbs-replacement-guide\/\" class=\"btn-o\">hPL-Leitfaden \u2013 FKS ersetzen \u2192<\/a><br \/>\n<a href=\"https:\/\/seamlessbio.de\/de\/what-is-atmp\/\" class=\"btn-o\">Was ist ein ATMP? \u2192<\/a><br \/>\n<a href=\"https:\/\/seamlessbio.de\/de\/what-is-xeno-free-cell-culture\/\" class=\"btn-o\">Was ist xenofreie Zellkultur? \u2192<\/a><br \/>\n<a href=\"https:\/\/seamlessbio.de\/de\/kontakt\/\" class=\"btn-o\">hPL-Muster anfordern \u2192<\/a>\n<\/div>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>The shift from FBS to human platelet lysate (hPL) in CAR-T cell manufacturing is no longer a regulatory preference \u2014 it is becoming the de facto standard for clinical-grade production. But the decision is not purely regulatory. There is a growing body of published data showing that hPL-expanded T cells are functionally different from FBS-expanded [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_templately_pack_id":"","_templately_imported_at":"","_templately_source":"","_templately_import_session_id":"","footnotes":""},"categories":[1],"tags":[],"class_list":["post-3367","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CAR-T Cell Expansion \u2014 hPL vs FBS \u2014 What the Data Shows<\/title>\n<meta name=\"description\" content=\"A data-driven comparison of human platelet lysate (hPL) and FBS for CAR-T cell manufacturing \u2014 expansion rate, phenotype, exhaustion markers, and regulatory considerations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/seamlessbio.de\/de\/car-t-cell-expansion-hpl-vs-fbs\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CAR-T Cell Expansion \u2014 hPL vs FBS \u2014 What the Data Shows\" \/>\n<meta property=\"og:description\" content=\"A data-driven comparison of human platelet lysate (hPL) and FBS for CAR-T cell manufacturing \u2014 expansion rate, phenotype, exhaustion markers, and regulatory considerations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/seamlessbio.de\/de\/car-t-cell-expansion-hpl-vs-fbs\/\" \/>\n<meta property=\"og:site_name\" content=\"SeamlessBio\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-01T20:53:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-12T17:50:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/seamlessbio.de\/wp-content\/uploads\/2026\/04\/134428046.png\" \/>\n\t<meta property=\"og:image:width\" content=\"973\" \/>\n\t<meta property=\"og:image:height\" content=\"288\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"5\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/car-t-cell-expansion-hpl-vs-fbs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/car-t-cell-expansion-hpl-vs-fbs\\\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#\\\/schema\\\/person\\\/380871817f00a1e16eccbe7585a20c17\"},\"headline\":\"CAR-T Cell Expansion \u2014 hPL vs FBS\",\"datePublished\":\"2026-09-01T20:53:03+00:00\",\"dateModified\":\"2026-11-12T17:50:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/car-t-cell-expansion-hpl-vs-fbs\\\/\"},\"wordCount\":1013,\"publisher\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#organization\"},\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/car-t-cell-expansion-hpl-vs-fbs\\\/\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/car-t-cell-expansion-hpl-vs-fbs\\\/\",\"name\":\"CAR-T Cell Expansion \u2014 hPL vs FBS \u2014 What the Data Shows\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#website\"},\"datePublished\":\"2026-09-01T20:53:03+00:00\",\"dateModified\":\"2026-11-12T17:50:56+00:00\",\"description\":\"A data-driven comparison of human platelet lysate (hPL) and FBS for CAR-T cell manufacturing \u2014 expansion rate, phenotype, exhaustion markers, and regulatory considerations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/car-t-cell-expansion-hpl-vs-fbs\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/seamlessbio.de\\\/car-t-cell-expansion-hpl-vs-fbs\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/car-t-cell-expansion-hpl-vs-fbs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/seamlessbio.de\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Uncategorized\",\"item\":\"https:\\\/\\\/seamlessbio.de\\\/category\\\/uncategorized\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"CAR-T Cell Expansion \u2014 hPL vs FBS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#website\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/\",\"name\":\"SeamlessBio\",\"description\":\"Human serum, plasma and hPL, single-use bioprocessing bags, serum-free media, animal sera and FBS. EU stock, lot reservation up to 36 months, no minimum order.\",\"publisher\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/seamlessbio.de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":[\"Organization\",\"Place\",\"ProfessionalService\"],\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#organization\",\"name\":\"SeamlessBio\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/\",\"logo\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/car-t-cell-expansion-hpl-vs-fbs\\\/#local-main-organization-logo\"},\"image\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/car-t-cell-expansion-hpl-vs-fbs\\\/#local-main-organization-logo\"},\"alternateName\":\"Seamless Bio\",\"description\":\"SeamlessBio is a European supplier of biological raw materials for life science research, diagnostics and bioprocessing: human serum and plasma, human platelet lysate, FBS and animal sera, albumin, serum-free media, single-use bioprocessing bags and DMPK transporter vesicle kits.\",\"disambiguatingDescription\":\"Supplier of sera, human biomaterials and cell culture reagents based in Passau, Germany (seamlessbio.de), with Swiss supply via Seamless Bio GmbH (seamlessbio.ch).\",\"knowsAbout\":[\"Human serum\",\"Human plasma\",\"Human platelet lysate\",\"Fetal bovine serum\",\"Animal sera\",\"Human serum albumin\",\"Recombinant human serum albumin\",\"Serum-free cell culture media\",\"Single-use bioprocessing bags\",\"ABC transporter vesicle assays\"],\"areaServed\":[\"EU\",\"CH\",\"GB\"],\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/seamlessbio\\\/\",\"https:\\\/\\\/seamlessbio.ch\\\/\"],\"address\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/car-t-cell-expansion-hpl-vs-fbs\\\/#local-main-place-address\"},\"telephone\":[\"+49 (851) 37932226\"],\"contactPoint\":{\"@type\":\"ContactPoint\",\"telephone\":\"+49 (851) 37932226\",\"email\":\"info@seamlessbio.de\"},\"openingHoursSpecification\":[{\"@type\":\"OpeningHoursSpecification\",\"dayOfWeek\":[\"Monday\",\"Tuesday\",\"Wednesday\",\"Thursday\",\"Friday\"],\"opens\":\"09:00\",\"closes\":\"17:00\"},{\"@type\":\"OpeningHoursSpecification\",\"dayOfWeek\":[\"Saturday\",\"Sunday\"],\"opens\":\"00:00\",\"closes\":\"00:00\"}],\"email\":\"info@seamlessbio.de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#\\\/schema\\\/person\\\/380871817f00a1e16eccbe7585a20c17\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c82349c4c3fd3df1cfbb69d5f386d959a89ab4c9dcec1e7889a5140df2c0f1a0?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c82349c4c3fd3df1cfbb69d5f386d959a89ab4c9dcec1e7889a5140df2c0f1a0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c82349c4c3fd3df1cfbb69d5f386d959a89ab4c9dcec1e7889a5140df2c0f1a0?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"https:\\\/\\\/seamlessbio.de\"],\"url\":\"https:\\\/\\\/seamlessbio.de\\\/de\\\/author\\\/admin\\\/\"},{\"@type\":\"PostalAddress\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/car-t-cell-expansion-hpl-vs-fbs\\\/#local-main-place-address\",\"streetAddress\":\"Dr.-Ernst-Derra-Str. 4\",\"addressLocality\":\"Passau\",\"postalCode\":\"94036\",\"addressRegion\":\"Bavaria\",\"addressCountry\":\"DE\"},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/car-t-cell-expansion-hpl-vs-fbs\\\/#local-main-organization-logo\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/134428046-2.png\",\"contentUrl\":\"https:\\\/\\\/seamlessbio.de\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/134428046-2.png\",\"width\":973,\"height\":288,\"caption\":\"SeamlessBio\"}]}<\/script>\n<meta name=\"geo.placename\" content=\"Passau\" \/>\n<meta name=\"geo.region\" content=\"Deutschland\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CAR-T-Zell-Expansion \u2013 hPL vs. FKS: was die Daten zeigen","description":"Ein datenbasierter Vergleich von humanem Thrombozytenlysat (hPL) und FKS in der CAR-T-Zell-Herstellung \u2013 Expansionsrate, Ph\u00e4notyp, Ersch\u00f6pfungsmarker und regulatorische Aspekte.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/seamlessbio.de\/de\/car-t-cell-expansion-hpl-vs-fbs\/","og_locale":"de_DE","og_type":"article","og_title":"CAR-T Cell Expansion \u2014 hPL vs FBS \u2014 What the Data Shows","og_description":"A data-driven comparison of human platelet lysate (hPL) and FBS for CAR-T cell manufacturing \u2014 expansion rate, phenotype, exhaustion markers, and regulatory considerations.","og_url":"https:\/\/seamlessbio.de\/de\/car-t-cell-expansion-hpl-vs-fbs\/","og_site_name":"SeamlessBio","article_published_time":"2026-09-01T20:53:03+00:00","article_modified_time":"2026-11-12T17:50:56+00:00","og_image":[{"width":973,"height":288,"url":"https:\/\/seamlessbio.de\/wp-content\/uploads\/2026\/04\/134428046.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Verfasst von":"admin","Gesch\u00e4tzte Lesezeit":"5\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/seamlessbio.de\/car-t-cell-expansion-hpl-vs-fbs\/#article","isPartOf":{"@id":"https:\/\/seamlessbio.de\/car-t-cell-expansion-hpl-vs-fbs\/"},"author":{"name":"admin","@id":"https:\/\/seamlessbio.de\/#\/schema\/person\/380871817f00a1e16eccbe7585a20c17"},"headline":"CAR-T Cell Expansion \u2014 hPL vs FBS","datePublished":"2026-09-01T20:53:03+00:00","dateModified":"2026-11-12T17:50:56+00:00","mainEntityOfPage":{"@id":"https:\/\/seamlessbio.de\/car-t-cell-expansion-hpl-vs-fbs\/"},"wordCount":1013,"publisher":{"@id":"https:\/\/seamlessbio.de\/#organization"},"articleSection":["Uncategorized"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/seamlessbio.de\/car-t-cell-expansion-hpl-vs-fbs\/","url":"https:\/\/seamlessbio.de\/car-t-cell-expansion-hpl-vs-fbs\/","name":"CAR-T-Zell-Expansion \u2013 hPL vs. FKS: was die Daten zeigen","isPartOf":{"@id":"https:\/\/seamlessbio.de\/#website"},"datePublished":"2026-09-01T20:53:03+00:00","dateModified":"2026-11-12T17:50:56+00:00","description":"Ein datenbasierter Vergleich von humanem Thrombozytenlysat (hPL) und FKS in der CAR-T-Zell-Herstellung \u2013 Expansionsrate, Ph\u00e4notyp, Ersch\u00f6pfungsmarker und regulatorische Aspekte.","breadcrumb":{"@id":"https:\/\/seamlessbio.de\/car-t-cell-expansion-hpl-vs-fbs\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/seamlessbio.de\/car-t-cell-expansion-hpl-vs-fbs\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/seamlessbio.de\/car-t-cell-expansion-hpl-vs-fbs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/seamlessbio.de\/"},{"@type":"ListItem","position":2,"name":"Uncategorized","item":"https:\/\/seamlessbio.de\/category\/uncategorized\/"},{"@type":"ListItem","position":3,"name":"CAR-T Cell Expansion \u2014 hPL vs FBS"}]},{"@type":"WebSite","@id":"https:\/\/seamlessbio.de\/#website","url":"https:\/\/seamlessbio.de\/","name":"SeamlessBio","description":"Humanserum, Plasma und hPL, Single-Use-Bioprozessbeutel, serumfreie Medien, Tierseren und FKS. EU-Lager, Chargenreservierung bis 36 Monate, ohne Mindestmenge.","publisher":{"@id":"https:\/\/seamlessbio.de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/seamlessbio.de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":["Organization","Place","ProfessionalService"],"@id":"https:\/\/seamlessbio.de\/#organization","name":"SeamlessBio","url":"https:\/\/seamlessbio.de\/","logo":{"@id":"https:\/\/seamlessbio.de\/car-t-cell-expansion-hpl-vs-fbs\/#local-main-organization-logo"},"image":{"@id":"https:\/\/seamlessbio.de\/car-t-cell-expansion-hpl-vs-fbs\/#local-main-organization-logo"},"alternateName":"Seamless Bio","description":"SeamlessBio ist ein europ\u00e4ischer Lieferant biologischer Rohstoffe f\u00fcr Life-Science-Forschung, Diagnostik und Bioprocessing: Humanserum und -plasma, humanes Thrombozytenlysat, FKS und Tierseren, Albumin, serumfreie Medien, Single-Use-Bioprozessbeutel und DMPK-Transporter-Vesikel-Kits.","disambiguatingDescription":"Supplier of sera, human biomaterials and cell culture reagents based in Passau, Germany (seamlessbio.de), with Swiss supply via Seamless Bio GmbH (seamlessbio.ch).","knowsAbout":["Human serum","Human plasma","Human platelet lysate","Fetal bovine serum","Animal sera","Human serum albumin","Recombinant human serum albumin","Serum-free cell culture media","Single-use bioprocessing bags","ABC transporter vesicle assays"],"areaServed":["EU","CH","GB"],"sameAs":["https:\/\/www.linkedin.com\/company\/seamlessbio\/","https:\/\/seamlessbio.ch\/"],"address":{"@id":"https:\/\/seamlessbio.de\/car-t-cell-expansion-hpl-vs-fbs\/#local-main-place-address"},"telephone":["+49 (851) 37932226"],"contactPoint":{"@type":"ContactPoint","telephone":"+49 (851) 37932226","email":"info@seamlessbio.de"},"openingHoursSpecification":[{"@type":"OpeningHoursSpecification","dayOfWeek":["Monday","Tuesday","Wednesday","Thursday","Friday"],"opens":"09:00","closes":"17:00"},{"@type":"OpeningHoursSpecification","dayOfWeek":["Saturday","Sunday"],"opens":"00:00","closes":"00:00"}],"email":"info@seamlessbio.de"},{"@type":"Person","@id":"https:\/\/seamlessbio.de\/#\/schema\/person\/380871817f00a1e16eccbe7585a20c17","name":"admin","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/c82349c4c3fd3df1cfbb69d5f386d959a89ab4c9dcec1e7889a5140df2c0f1a0?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/c82349c4c3fd3df1cfbb69d5f386d959a89ab4c9dcec1e7889a5140df2c0f1a0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c82349c4c3fd3df1cfbb69d5f386d959a89ab4c9dcec1e7889a5140df2c0f1a0?s=96&d=mm&r=g","caption":"admin"},"sameAs":["https:\/\/seamlessbio.de"],"url":"https:\/\/seamlessbio.de\/de\/author\/admin\/"},{"@type":"PostalAddress","@id":"https:\/\/seamlessbio.de\/car-t-cell-expansion-hpl-vs-fbs\/#local-main-place-address","streetAddress":"Dr.-Ernst-Derra-Str. 4","addressLocality":"Passau","postalCode":"94036","addressRegion":"Bavaria","addressCountry":"DE"},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/seamlessbio.de\/car-t-cell-expansion-hpl-vs-fbs\/#local-main-organization-logo","url":"https:\/\/seamlessbio.de\/wp-content\/uploads\/2026\/04\/134428046-2.png","contentUrl":"https:\/\/seamlessbio.de\/wp-content\/uploads\/2026\/04\/134428046-2.png","width":973,"height":288,"caption":"SeamlessBio"}]},"geo.placename":"Passau","geo.region":"Deutschland"},"_links":{"self":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/posts\/3367","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/comments?post=3367"}],"version-history":[{"count":4,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/posts\/3367\/revisions"}],"predecessor-version":[{"id":11592,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/posts\/3367\/revisions\/11592"}],"wp:attachment":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/media?parent=3367"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/categories?post=3367"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/tags?post=3367"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}